Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 1999

View Archived Issues

Cephalon provides update on product development programs

Encouraging survival data reported for Genta's G-3139 in malignant melanoma trial

Novartis pursues development of Src kinase inhibitors for osteoporosis

New study indicates another potential indication for pentoxifylline

Inex files to begin pivotal trial of Onco TCS

Flamel Technologies to initiate phase I study of Basulin

Is depression an endocrine system disorder?

First launch for Bone Care's novel vitamin D prohormone

New cardiovascular agents from Yamanouchi block If current

Nikken Chemicals prepares PDE4 inhibitors useful for allergic and inflammatory disorders

PLA2 inhibitors remain a focus of research at Genetics Institute

Potent and selective vitronectin antagonists developed at SmithKline Beecham

CRC investigators present proof that the angiogenesis theory works in patients

Manganese chelates disclosed by Bracco, Dibra for MRI contrast imaging

P&U reports advance in the field of oxazolidinone antibacterials at ICAAC

More good news for flu drug: oseltamivir featured in JAMA article

NCI supports further study of anticancer drugs at Lorus

Acylides as new third-generation macrolide antibiotics

New tricyclic acylides exhibit improved antibacterial activity

Over 10 abstracts related to nonfluoroquinolones presented by P&G at ICAAC

Monoclonal antibodies with potential in AIDS Rx available for licensing from NIH

TAK-778, the first nonendogenous compound able to promote new bone formation and heal breaks

FDA approves new indication for Topamax

Oligo Therapeutics designs completely new class of antimicrobial agents

BioCryst's cyclopentane influenza neuraminidase inhibitors profiled: competition for Tamiflu?

FDA approves Pfizer's Tikosyn

Abgenix completes phase I/II clinical trial with ABX-IL-8

TheraTech and Procter & Gamble rework agreements for female HRT products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...